Cuban Drug Heberprot-P already registered in 19 Countries
Cuban Drug Heberprot-P already registered in 19 Countries
HAVANA, Cuba, Nov 4 (acn) Heberprot-P, unique of its kind in the world to avoid amputation in diabetic foot ulcers, is registered in 19 countries, a Cuban expert announced in Havana.
In statements to ACN, Dr. Manuel Raíces, researcher at the Center for Genetic Engineering and Biotechnology (CIGB by its Spanish acronym), said that with such therapy they have treated more than 132,000 patients worldwide with successful results.
From that total, more than 24,000 are Cubans and the relative risk of amputation has been reduced by 71 percent, generating a high quality of life for the population, the CIGB researcher stated, whose entity is actually participating in the 31st edition of Havana International Fair, FIHAV 2013.
The expert added that over 60 percent of patients who have underwent therapies using this innovative product in the Caribbean nation are treated in the system of Primary Health Care (PHC), which shows the perception of risk within diabetic population.
Dr. Raices noted that before 2016 it is expected that more than 90 percent of Cuban population to attend the PHC, which will considerably reduce the risk of amputation.
More:
http://www.canadiannetworkoncuba.ca/index.php?option=com_content&view=article&id=433:news-on-cuba-november-5-2013&catid=62:cuba-news&Itemid=146